Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMTXNASDAQ:IOVANASDAQ:KALVNASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMTXImmatics$6.10-0.3%$4.91$3.30▼$13.23$741.46M0.83655,794 shs433,411 shsIOVAIovance Biotherapeutics$2.08-7.1%$2.55$1.64▼$12.51$694.58M0.868.93 million shs12.59 million shsKALVKalVista Pharmaceuticals$13.04+0.6%$12.35$7.30▼$15.50$648.30M-0.01450,223 shs1.79 million shsOGIOrganigram$1.43+2.1%$1.21$0.85▼$2.08$191.45M1.37658,043 shs551,845 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMTXImmatics0.00%+2.51%+29.11%+22.89%-53.00%IOVAIovance Biotherapeutics0.00%+9.27%+34.94%-40.11%-72.55%KALVKalVista Pharmaceuticals0.00%-9.75%+8.63%+3.76%+7.37%OGIOrganigram0.00%+3.70%+2.94%+30.84%-8.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMTXImmatics2.6044 of 5 stars3.63.00.00.03.41.70.0IOVAIovance Biotherapeutics4.6355 of 5 stars4.31.00.04.22.24.21.3KALVKalVista Pharmaceuticals3.9757 of 5 stars3.60.00.04.43.12.50.6OGIOrganigram0.6201 of 5 stars0.01.00.00.03.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMTXImmatics 3.20Buy$14.67140.44% UpsideIOVAIovance Biotherapeutics 2.50Moderate Buy$13.30539.42% UpsideKALVKalVista Pharmaceuticals 3.13Buy$24.8390.44% UpsideOGIOrganigram 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest OGI, IOVA, KALV, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/16/2025IOVAIovance BiotherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$17.00 ➝ $2.005/12/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $8.005/12/2025IOVAIovance BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.005/12/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/12/2025IOVAIovance BiotherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/9/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.005/9/2025IOVAIovance BiotherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/9/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $20.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMTXImmatics$144.15M5.14N/AN/A$2.88 per share2.12IOVAIovance Biotherapeutics$212.68M3.27N/AN/A$2.28 per share0.91KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/AOGIOrganigram$194.09M0.99N/AN/A$1.83 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)IOVAIovance Biotherapeutics-$444.04M-$1.24N/AN/AN/A-451.25%-58.43%-45.48%8/6/2025 (Estimated)KALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-103.92%-88.06%7/10/2025 (Estimated)OGIOrganigram-$33.39M$0.10N/AN/AN/A-31.69%-8.59%-6.54%8/12/2025 (Estimated)Latest OGI, IOVA, KALV, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83N/AN/AN/AN/AN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMTXImmaticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMTXImmaticsN/A3.983.98IOVAIovance BiotherapeuticsN/A4.223.90KALVKalVista PharmaceuticalsN/A6.876.87OGIOrganigramN/A3.361.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMTXImmatics64.41%IOVAIovance Biotherapeutics77.03%KALVKalVista PharmaceuticalsN/AOGIOrganigram34.63%Insider OwnershipCompanyInsider OwnershipIMTXImmatics3.30%IOVAIovance Biotherapeutics10.30%KALVKalVista Pharmaceuticals10.50%OGIOrganigram0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMTXImmatics260121.55 million115.42 millionOptionableIOVAIovance Biotherapeutics500333.93 million267.90 millionOptionableKALVKalVista Pharmaceuticals10049.72 million44.23 millionOptionableOGIOrganigram860133.88 million126.10 millionOptionableOGI, IOVA, KALV, and IMTX HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Trims Holdings in Organigram Holdings Inc. (NASDAQ:OGI)June 13 at 3:07 AM | marketbeat.comMillennium Management LLC Trims Stock Holdings in Organigram Holdings Inc. (NASDAQ:OGI)June 6, 2025 | marketbeat.comJune 2025 Watchlist: Best Canadian Cannabis Stocks for GrowthMay 31, 2025 | marijuanastocks.comTidal Investments LLC Sells 225,184 Shares of Organigram Holdings Inc. (NASDAQ:OGI)May 24, 2025 | marketbeat.comEarnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%May 14, 2025 | uk.investing.comOrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)May 12, 2025 | zacks.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comInsights Ahead: OrganiGram Holdings's Quarterly EarningsMay 9, 2025 | benzinga.comOrganigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export AwardsMay 5, 2025 | finance.yahoo.comOrganigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export AwardsMay 5, 2025 | businesswire.comOrganigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025May 2, 2025 | businesswire.comOrganigram Global’s Products Recognized at the CNB AwardsApril 24, 2025 | finance.yahoo.comOrganigram Global's Products Recognized at the CNB AwardsApril 24, 2025 | businesswire.comOrganigram Global Shares Recording of its OG Investor SessionApril 22, 2025 | businesswire.comOrganigram Global Announces Acquisition Of Collective Project Limited - Quick FactsApril 3, 2025 | nasdaq.comOrganigram Global Inc. (OGI.TO)April 2, 2025 | ca.finance.yahoo.comOrganigram Global to Host the OG Investor Session, its Inaugural Virtual Event for Investors, and Announcement of Name Change on TSX and NASDAQApril 2, 2025 | businesswire.comOrganigram acquires Collective Project for C$6.2MApril 2, 2025 | markets.businessinsider.comTop 5 cannabis stocks with operations in CanadaApril 1, 2025 | msn.comStocks in play: Organigram Global Inc.April 1, 2025 | ca.finance.yahoo.comOrganigram Enters U.S. Through Acquisition of Collective Project BeveragesApril 1, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPE3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketBy Chris Markoch | May 22, 2025View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketOGI, IOVA, KALV, and IMTX Company DescriptionsImmatics NASDAQ:IMTX$6.10 -0.02 (-0.33%) Closing price 04:00 PM EasternExtended Trading$6.10 +0.01 (+0.08%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Iovance Biotherapeutics NASDAQ:IOVA$2.08 -0.16 (-7.14%) Closing price 04:00 PM EasternExtended Trading$2.09 +0.01 (+0.48%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.KalVista Pharmaceuticals NASDAQ:KALV$13.04 +0.08 (+0.62%) Closing price 04:00 PM EasternExtended Trading$12.97 -0.07 (-0.57%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Organigram NASDAQ:OGI$1.43 +0.03 (+2.14%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.70%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
